Document is current
Any future updates will be listed below
-
Authors
Roelz, Roland
Schubach, Fabian https://orcid.org/0000-0002-9387-019X
Coenen, Volker A.
Jenkner, Carolin
Scheiwe, Christian
Grauvogel, Jürgen
Niesen, Wolf-Dirk
Urbach, Horst
Taschner, Christian
Seufert, Jochen
Kätzler, Jürgen
Beck, Jürgen
Reinacher, Peter C.
-
Funding
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2016_A208, 2016_A208)
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Received: 8 October 2020
Accepted: 18 March 2021
First Online: 15 April 2021
Declarations
:
: The SPLASH trial was approved by the Ethics Committee of the University of Freiburg (reference no.: EK-FR 394/18), the German National Competent Authority, and the Federal Institute for Drugs and Medical Devices (<i>Bundesinstitut für Arzneimittel und Medizinprodukte</i>, <i>BfArM</i>, reference no.: 4043052) and notified to the German Federal Radioprotection Agency (<i>Bundesamt für Strahlenschutz</i> (<i>BfS</i>)). Written informed consent will be obtained for every subject participating in this clinical trial.
: Model informed consent forms (German version) can be obtained from the corresponding author upon request.
: Dr. Roelz and Dr. Reinacher report a research grant from Else Kröner-Fresenius-Stiftung for the conduct of the study. Dr. Reinacher reports personal fees from Fraunhofer-Gesellschaft (Munich, Germany), Boston Scientific (Marlborough, MA, USA), Brainlab (Munich, Germany), and Inomed (Emmendingen, Germany) outside the submitted work. The other authors declare that they have no competing interests.
